Skip to main content
Evidence Snapshot

ALK tyrosine kinase receptor

CHEMBL4247 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4247
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats ALK tyrosine kinase receptor as ChEMBL target CHEMBL4247, mapped to UniProt Q9UM73. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
ALK tyrosine kinase receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4247
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9UM73
ALK tyrosine kinase receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why ALK tyrosine kinase receptor matters

As of 2026-09-13

ALK tyrosine kinase receptor is reviewed as ALK tyrosine kinase receptor (UniProt Q9UM73); ALK tyrosine kinase receptor shows approved-linked disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.; 9 linked drugs keep this evidence frame grounded.; the current evidence base includes 35 approved drugs, 4520 compounds, and 1345 assays, with lead potency reaching pChEMBL 10.2.

Disease context
non-small cell lung carcinoma

ALK tyrosine kinase receptor shows approved-linked disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALECTINIB HYDROCHLORIDE, BRIGATINIB, CERITINIB.

Start review with non-small cell lung carcinoma because it currently carries approved-linked support. Linked drugs include ALECTINIB HYDROCHLORIDE, BRIGATINIB, CERITINIB, CONTELTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 9 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 35 approved drugs, 4520 compounds, and 1345 assays for this target. The dominant activity type is IC50. CHEMBL3397300 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL3397300 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
35 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why ALK tyrosine kinase receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UM73, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why non-small cell lung carcinoma is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4520
Total Compounds
1345
Total Assays
35
Approved Drugs
IC50: 4356.0, KI: 946.0, EC50: 9.0, KD: 215.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3397300
 10.2 IC50 —
No preferred name
CHEMBL3286823
 10.0 Ki —
No preferred name
CHEMBL3286825
 10.0 Ki —
No preferred name
CHEMBL5593687
 10.0 IC50 —
No preferred name
CHEMBL3286826
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
REPOTRECTINIB
CHEMBL4298138
 2023
ENTRECTINIB
CHEMBL1983268
 2019
FEDRATINIB
CHEMBL1287853
 2019
LORLATINIB
CHEMBL3286830
 2018
GILTERITINIB
CHEMBL3301622
 2018
BRIGATINIB
CHEMBL3545311
 2017
MIDOSTAURIN
CHEMBL608533
 2017
ALECTINIB
CHEMBL1738797
 2015
OSIMERTINIB
CHEMBL3353410
 2015
CERITINIB
CHEMBL2403108
 2014
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
CRIZOTINIB
CHEMBL601719
 2011
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4247